PDX model details
| PDX ID |
167.2M |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
27 |
| Average PDX Generation Time (days +/- SEM) |
48 ± 2 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304; 33620092 |
| |
|
| Markers |
167.2M |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 167.2M |
PTEN |
-4.339 |
0.099 |
Homdel
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
PTEN |
-1.688 |
0.621 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
APC |
-1.656 |
0.635 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
ARID2 |
0.564 |
2.956 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
KMT2D |
0.564 |
2.956 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
ZFHX3 |
0.617 |
3.066 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
CHD7 |
0.631 |
3.097 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
MYC |
0.631 |
3.097 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
KMT2A |
0.740 |
3.341 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
SPEN |
0.977 |
3.935 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
CCND1 |
1.130 |
4.377 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
PIK3CB |
1.283 |
4.868 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
PIK3CA |
1.283 |
4.868 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 167.2M |
AR |
1.581 |
2.991 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
Clinical Information
| Sample Number |
167.2M |
| Sample Site |
Spine |
| Sample source |
Surgery |
| Pathology Tumour Diagnosis |
Adenocarcinoma |
| Gleason Score |
9 |
| Primary Gleason Score |
4 |
| Secondary Gleason Score |
5 |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, docetaxel |
| |
|
Patient Information
| Patient Number |
167 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
5.2 |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download Plot
This table displays curated sequence variants
No information in Drug dosing Table